

Haematologica
HAEMATOL/2017/174953
Version 3

Treatment outcome in a population-based ‘real-world’ cohort of chronic myeloid leukemia patients

Inge G.P. Geelen, Noortje Thielen, Jeroen J.W.M. Janssen, Mels Hoogendoorn, Tanja J.A. Roosma, Sten P. Willemsen, Otto Visser, Jan J. Cornelissen, and Peter E. Westerweel

Disclosures: IG, NT, MH, TR, SW, OV and JC have nothing to disclose. Support for work outside the submitted work during the 36 months prior to publication was received by JJ (BMS, Novartis, Pfizer, Ariad) and PW (Bayer, BMS, Celgene, Gilead, Novartis, Pfizer, Takeda, TEVA)

Contributions: I.G., N.T., O.V., J.J. and P.W. designed the study; T.R., N.T., I.G. and M.H. carried out data collection; I.G. and S.W. performed the statistical analysis; I.G., J.J., J.C. and P.W. analyzed the data, I.G. and P.W. wrote the initial draft of the manuscript. All authors contributed to interpretation of the results and revision of the paper.